Divi's Laboratories Limited is a leading pharmaceutical company known for manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals with a strong global presence in 100 countries.

The company has launched its third manufacturing unit in Kakinada, enhancing in-house production capacity and backward integration, showcasing its strategic commitment to scaling operations.

In Q2 FY2026, Divi's achieved a total income of ₹2,860 crores, marking a 17% increase year-on-year, despite pricing pressures in the generic segment, demonstrating resilience and effective cost management.

The custom synthesis segment continues to grow robustly, contributing 56% to product mix revenues, underlining Divi's capability to cater to global innovators with advanced pharmaceutical synthesis requirements.

Divi's Laboratories maintains a global export focus with 90% of its revenue derived from international markets, primarily Europe and the U.S., reflecting its strong international market positioning.